Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses

References

• Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–13. doi:10.1038/s41591-018-0014-x.
   PubMed Web of Science ®Google Scholar
• Kennedy LB, Salama AKS. A review of cancer immunotherapy toxicity. CA Cancer J Clin. 2020;70(2):86–104. doi:10.3322/caac.21596
   PubMed Web of Science ®Google Scholar
• Mayoux M, Roller A, Pulko V, Sammicheli S, Chen S, Sum E, Jost C, Fransen MF, Buser RB, Kowanetz M, et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci Transl Med. 2020;12(534):eaav7431. doi:10.1126/scitranslmed.aav7431
   PubMed Web of Science ®Google Scholar
• Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060
   PubMed Web of Science ®Google Scholar
• Batlle E, Massagué J. Transforming growth factor-β signaling in immunity and cancer. Immunity. 2019;50(4):924–940. doi:10.1016/j.immuni.2019.03.024
   PubMed Web of Science ®Google Scholar
• Derynck R, Turley SJ, Akhurst RJ. TGFβ biology in cancer progression and immunotherapy. Nat Rev Clin Oncol. 2021;18(1):9–34. doi:10.1038/s41571-020-0403-1
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Sancho E, Batlle E. Overcoming TGFβ-mediated immune evasion in cancer. Nat Rev Cancer. 2022;22(1):25–44. doi:10.1038/s41568-021-00413-6
   PubMed Web of Science ®Google Scholar
• Chen B, Mu C, Zhang Z, He X, Liu X. The love-hate relationship between TGF-β signaling and the immune system during development and tumorigenesis. Front Immunol. 2022;13:891268. doi:10.3389/fimmu.2022.891268
   PubMed Web of Science ®Google Scholar
• Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, Sevillano M, Ibiza S, Cañellas A, Hernando-Momblona X, et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538–543. doi:10.1038/nature25492
   PubMed Web of Science ®Google Scholar
• Gulley JL, Schlom J, Barcellos-Hoff MH, Wang X-J, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment. Mol Oncol. 2022;16(11):2117–2134. doi:10.1002/1878-0261.13146
   PubMed Web of Science ®Google Scholar
• Navarro R, Tapia-Galisteo A, Martín-García L, Tarín C, Corbacho C, Gómez-López G, Sánchez-Tirado E, Campuzano S, González-Cortés A, Yáñez-Sedeño P, et al. TGF-β-induced IGFBP-3 is a key paracrine factor from activated pericytes that promotes colorectal cancer cell migration and invasion. Mol Oncol. 2020;14(10):2609–2628. doi:10.1002/1878-0261.12779.
   PubMed Web of Science ®Google Scholar
• Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel EE, Koeppen H, Astarita JL, Cubas R, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544–548. doi:10.1038/nature25501
   PubMed Web of Science ®Google Scholar
• Greco R, Qu H, Qu H, Theilhaber J, Shapiro G, Gregory R, Winter C, Malkova N, Sun F, Jaworski J, et al. Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade. Oncoimmunology. 2020;9(1):1811605. doi:10.1080/2162402X.2020.1811605
   PubMed Web of Science ®Google Scholar
• Teicher BA. TGFβ-Directed Therapeutics: 2020. Pharmacology & Therapeutics. 2021;217:107666. doi:10.1016/j.pharmthera.2020.107666
   PubMed Web of Science ®Google Scholar
• Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP, Perez-Gracia JL. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One. 2014;9(3):e90353. doi:10.1371/journal.pone.0090353
   PubMed Web of Science ®Google Scholar
• Teixeira AF, Ten Dijke P, Zhu H-J. On-target anti-TGF-β therapies are not succeeding in clinical cancer treatments: what are remaining challenges? Front Cell Dev Biol. 2020;8:605. doi:10.3389/fcell.2020.00605
   PubMed Web of Science ®Google Scholar
• Colak S, Ten Dijke P. Targeting TGF-β signaling in cancer. Trends Cancer. 2017;3(1):56–71. doi:10.1016/j.trecan.2016.11.008
   PubMed Web of Science ®Google Scholar
• Robbrecht D, Doger B, Grob J-J, Bechter OE, de Miguel MJ, Vieito M, Schadendorf D, Curigliano G, Borbath I, Butler MO, et al. Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors. J Clin Oncol. 2022;40(16_suppl):2524–2524. doi:10.1200/JCO.2022.40.16_suppl.2524
   PubMed Web of Science ®Google Scholar
• Melisi D, Oh D-Y, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, et al. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. J Immunother Cancer. 2021;9(3):e002068. doi:10.1136/jitc-2020-002068
   PubMed Web of Science ®Google Scholar
• de Miguel M, Umana P, de Morais AL G, Moreno V, Calvo E. T-cell-engaging therapy for solid tumors. Clin Cancer Res. 2021;27(6):1595–1603. doi:10.1158/1078-0432.CCR-20-2448
   PubMed Web of Science ®Google Scholar
• Blanco B, Compte M, Lykkemark S, Sanz L, Alvarez-Vallina L. T cell-redirecting strategies to “STAb” tumors: beyond CARs and bispecific antibodies. Trends Immunol. 2019;40(3):243–257. doi:10.1016/j.it.2019.01.008
   PubMed Web of Science ®Google Scholar
• Goebeler M-E, Bargou RC. T cell-engaging therapies — BiTEs and beyond. Nat Rev Clin Oncol. 2020;17(7):418–434. doi:10.1038/s41571-020-0347-5
   PubMed Web of Science ®Google Scholar
• Tapia-Galisteo A, Sánchez Rodríguez Í, Aguilar-Sopeña O, Harwood SL, Narbona J, Ferreras Gutierrez M, Navarro R, Martín-García L, Corbacho C, Compte M, et al. Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. Oncoimmunology. 2022;11(1):2034355. doi:10.1080/2162402X.2022.2034355
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977. doi:10.1126/science.1158545
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Ko C-W, Deisseroth A, Yancey CL, Candau-Chacon R, Chiu H-J, Gehrke BJ, Gomez-Broughton C, Kane RC, Kirshner S, et al. FDA Approval: Blinatumomab. Clin Cancer Res. 2015;21(18):4035–4039. doi:10.1158/1078-0432.CCR-15-0612
   Web of Science ®Google Scholar
• Antibody therapeutics approved or in regulatory review in the EU or US. Antib Soc. [accessed 2023 Aug 6]. https://www.antibodysociety.org/resources/approved-antibodies/
   Google Scholar
• Elshiaty M, Schindler H, Christopoulos P. Principles and current clinical landscape of multispecific antibodies against cancer. Int J Mol Sci. 2021;22(11):5632. doi:10.3390/ijms22115632
   PubMed Web of Science ®Google Scholar
• Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024 Mar 6. 10.1038/s41573-024-00896-6
   Web of Science ®Google Scholar
• Ahn M-J, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee J-S, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389(22):2063–2075. doi:10.1056/NEJMoa2307980
   PubMed Web of Science ®Google Scholar
• Wagner J, Wickman E, DeRenzo C, Gottschalk S. CAR T cell therapy for solid tumors: bright future or dark reality?. Mol Ther J Am Soc Gene Ther. 2020;28(11):2320–2339. doi:10.1016/j.ymthe.2020.09.015
   PubMed Web of Science ®Google Scholar
• Maalej KM, Merhi M, Inchakalody VP, Mestiri S, Alam M, Maccalli C, Cherif H, Uddin S, Steinhoff M, Marincola FM, et al. CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol Cancer. 2023;22(1):20. doi:10.1186/s12943-023-01723-z
   PubMed Web of Science ®Google Scholar
• Khan SA, Joyce J, Tsuda T. Quantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassay. BMC Res Notes. 2012;5(1):636. doi:10.1186/1756-0500-5-636
   PubMedGoogle Scholar
• Schmitz KR, Bagchi A, Roovers RC, van Bergen En Henegouwen PMP, Ferguson KM. Structural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domains. Struct Lond Engl 1993. 2013;21(7):1214–1224. doi:10.1016/j.str.2013.05.008
   Google Scholar
• Sánchez-Martínez D, Baroni ML, Gutierrez-Agüera F, Roca-Ho H, Blanch-Lombarte O, González-García S, Torrebadell M, Junca J, Ramírez-Orellana M, Velasco-Hernández T, et al. Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia. Blood. 2019;133(21):2291–2304. doi:10.1182/blood-2018-10-882944
   PubMed Web of Science ®Google Scholar
• Massagué J. Tgfbeta in Cancer. Cell. 2008;134(2):215–230. doi:10.1016/j.cell.2008.07.001
   PubMed Web of Science ®Google Scholar
• Narayan V, Barber-Rotenberg JS, Jung I-Y, Lacey SF, Rech AJ, Davis MM, Hwang W-T, Lal P, Carpenter EL, Maude SL, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022;28(4):724–734. doi:10.1038/s41591-022-01726-1
   PubMed Web of Science ®Google Scholar
• Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernández VM, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10(424):eaan5488. doi:10.1126/scitranslmed.aan5488
   PubMed Web of Science ®Google Scholar
• Lan Y, Yeung T-L, Huang H, Wegener AA, Saha S, Toister-Achituv M, Jenkins MH, Chiu L-Y, Lazorchak A, Tarcic O, et al. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses. J Immunother Cancer. 2022;10(7):e004122. doi:10.1136/jitc-2021-004122
   PubMed Web of Science ®Google Scholar
• Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JL, Palena C, Schlom J. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1):e000433. doi:10.1136/jitc-2019-000433
   PubMed Web of Science ®Google Scholar
• Zhang J, Yi J, Zhou P. Development of bispecific antibodies in China: overview and prospects. Antib Ther. 2020;3(2):126–145. doi:10.1093/abt/tbaa011
   PubMedGoogle Scholar
• Cheng B, Ding K, Chen P, Ji J, Luo T, Guo X, Qiu W, Ma C, Meng X, Wang J, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun Lond Engl. 2022;42(1):17–36. doi:10.1002/cac2.12244
   PubMed Web of Science ®Google Scholar
• Feng J, Tang D, Wang J, Zhou Q, Peng J, Lou H, Sun Y, Cai Y, Chen H, Yang J, et al. SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGFβ, for Recurrent or metastatic cervical cancer: a clinical expansion cohort of a phase i study. Clin Cancer Res. 2022 Jun 2;28(24):5297–5305. doi:10.1158/1078-0432.CCR-22-0346
   PubMed Web of Science ®Google Scholar
• Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, Luo S, Zhou P, Wu K. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1. J Hematol Oncol. 2021;14(1):27. doi:10.1186/s13045-021-01045-x
   PubMed Web of Science ®Google Scholar
• Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, Li N, Zhou P, Chu Q, Wu K. Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021;14(1):146. doi:10.1186/s13045-021-01155-6
   PubMed Web of Science ®Google Scholar
• Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, Zhou P, Dai Z, Wu K. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12):e005543. doi:10.1136/jitc-2022-005543
   PubMed Web of Science ®Google Scholar
• Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors. Front Immunol. 2017;8:1287. doi:10.3389/fimmu.2017.01287
   PubMed Web of Science ®Google Scholar
• Austin RJ, Lemon BD, Aaron WH, Barath M, Culp PA, DuBridge RB, Evnin LB, Jones A, Panchal A, Patnaik P, et al. TriTACs, a novel class of T-Cell-engaging protein constructs designed for the treatment of solid tumors. Mol Cancer Ther. 2021;20(1):109–120. doi:10.1158/1535-7163.MCT-20-0061
   PubMed Web of Science ®Google Scholar
• Hangiu O, Compte M, Dinesen A, Navarro R, Tapia-Galisteo A, Mandrup OA, Erce-Llamazares A, Lázaro-Gorines R, Nehme-Álvarez D, Domínguez-Alonso C, et al. Tumor targeted 4-1BB agonist antibody-albumin fusions with high affinity to FcRn induce anti-tumor immunity without toxicity. iScience. 2022;25(9):104958. doi:10.1016/j.isci.2022.104958
   PubMed Web of Science ®Google Scholar
• Blanco B, Ramírez-Fernández Á, Bueno C, Argemí-Muntadas L, Fuentes P, Aguilar-Sopeña Ó, Gutierrez-Agüera F, Zanetti SR, Tapia-Galisteo A, Díez-Alonso L, et al. Overcoming CAR-Mediated CD19 downmodulation and leukemia relapse with T lymphocytes secreting anti-CD19 T-cell engagers. Cancer Immunol Res. 2022;10(4):498–511. doi:10.1158/2326-6066.CIR-21-0853
   PubMed Web of Science ®Google Scholar
• Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37(9):1049–1058. doi:10.1038/s41587-019-0192-1
   PubMed Web of Science ®Google Scholar
• Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, Song M, Miele MM, Li Z, Wang P, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol. 2018;36(9):847–856. doi:10.1038/nbt.4195
   PubMed Web of Science ®Google Scholar
• Suarez ER, Chang D-K, Sun J, Sui J, Freeman GJ, Signoretti S, Zhu Q, Marasco WA. Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget. 2016;7(23):34341–34355. doi:10.18632/oncotarget.9114
   PubMed Web of Science ®Google Scholar